IPCA Labs: Strong margins to sustain even post-COVID opportunities Trading Calls - Equity F&O June 2, 2021Recommendations In spite of the extraordinary sales of Hydroxychloroquine in FY21, IPCA Labs expects a 9-10 per cent growth in topline for FY22 Anubhav Sahu
